[PDF][PDF] Five-year follow-up of nivolumab in previously treated advanced non–small-cell lung cancer: results from the CA209-003 study
S Gettinger, L Horn, D Jackman… - Journal of Clinical …, 2018 - clf1.medpagetoday.com
Journal of Clinical Oncology, 2018•clf1.medpagetoday.com
Purpose In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor
antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non–
small-cell lung cancer (NSCLC). We report 5-year follow-up results from an early phase I
study of nivolumab in this patient population and describe characteristics of 5-year survivors.
antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non–
small-cell lung cancer (NSCLC). We report 5-year follow-up results from an early phase I
study of nivolumab in this patient population and describe characteristics of 5-year survivors.
Purpose
In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non–small-cell lung cancer (NSCLC). We report 5-year follow-up results from an early phase I study of nivolumab in this patient population and describe characteristics of 5-year survivors.
clf1.medpagetoday.com